477775-77-2

Usage

Uses

Used in Bioconjugation:
m-PEG3-NHS carbonate is used as a bioconjugation agent for the covalent attachment of biomolecules to other molecules or surfaces. The amine reactivity of the succinimidyl carbonate group enables the formation of stable amide bonds, which is crucial for creating stable and functional bioconjugates.
Used in Drug Delivery Systems:
In the pharmaceutical industry, m-PEG3-NHS carbonate is used as a component in the design of drug delivery systems. The hydrophilic PEG linker improves the solubility and bioavailability of drugs, while the amine-reactive succinimidyl carbonate group allows for the covalent attachment of drug molecules to the delivery system, enhancing their stability and targeted delivery.
Used in Diagnostics:
m-PEG3-NHS carbonate is also utilized in the development of diagnostic tools. The amine-reactive group can be used to attach diagnostic agents, such as imaging labels or markers, to biomolecules, enabling the detection and monitoring of various biological processes.
Used in Material Science:
In the field of material science, m-PEG3-NHS carbonate is employed as a modifier to improve the properties of materials. The hydrophilic PEG linker can be used to enhance the water solubility and biocompatibility of materials, while the amine-reactive group allows for the covalent attachment of functional groups or other molecules to the material, tailoring its properties for specific applications.

Upstream product

• 74124-79-1 di(succinimido) carbonate 
• 112-35-6 triethylene glucol monomethyl ether 
• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 105292-71-5 2-[2-(2-methoxyethoxy)ethoxy]ethyl chloroformate 

Relevant academic research and scientific papers

COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER

The present invention provides a means for treating and/or preventing peripheral nerve disorder by facilitating regeneration of peripheral nerves. Specifically, the present invention provides a composition for treating and/or preventing peripheral nerve d

PROTEASE INHIBITORS HAVING ENHANCED FEATURES

Provided herein (among other things) are protease inhibitor compounds having enhanced features, along with methods for administering such compounds. For example, the subject compounds can be administered without concomitant administration of a CYP3A4 inhibitor, have increased therapeutic index and/or increased potency, and are low-resistance inducing in nature.

Lissencephaly therapeutic agent

An object of the present invention is to provide a medicament and method for treating lissencephaly patients. The present invention provides a lissencephaly therapeutic or preventive agent comprising a compound represented by the general formula (I): wher

LISSENCEPHALY THERAPEUTIC AGENT

An object of the present invention is to provide a medicament and method for treating lissencephaly patients. The present invention provides a lissencephaly therapeutic or preventive agent comprising a compound represented by the general formula (I): wher

Bna Conjugates and Methods of Use

Modified natriuretic compounds and conjugates thereof are disclosed in the present invention. In particular, conjugated forms of hBNP are provided that include at least one modifying moiety attached thereto. The modified natriuretic compound conjugates retain activity for stimulating cGMP production, binding to NPR-A receptor, decreasing arterial blood pressure and in some embodiments an improved half-life in circulation as compared to unmodified counterpart natriuretic compounds. Oral, parenteral, enteral, subcutaneous, pulmonary, and intravenous forms of the compounds and conjugates may be prepared as treatments and/or therapies for heart conditions particularly congestive heart failure. Modifying moieties comprising oligomeric structures having a variety of lengths and configurations are also disclosed. Analogs of the hBNP compound are also disclosed, having an amino acid sequence that is other than the native sequence.

Molecular design to enhance the penetration into the retina via ocular instillation

To investigate the molecular design of drugs that have good penetration into the retina from anterior segment of the eye via ocular instillation, we optimized the length of methoxyethylene glycol chain (mEG) in the P3 region of an oral bioavailable calpain inhibitor SNJ-1945 (2) as a model compound. Modulation of the mEG length led to the optimal balance between hydrophilicity and lipophilicity and provided the compound with higher retinal exposure via ocular instillation. Incorporation of a mEG moiety would be a useful and convenient approach to attain high intraocular penetration.

Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof

Fatty acid compositions for administration of of pharmaceutical agents, such as proteins and peptides, protein and peptide conjugates, and/or cation-polypeptide conjugate complexes. In particular, the invention provides a solid pharmaceutical composition

ALPHA-KETOAMIDE DERIVATIVE, AND PRODUCTION METHOD AND USE THEREOF

The present invention provides a compound represented by the formula (I): (INSERT CHEMICAL FORMULA) (wherein R1 is a lower alkyl substituted by a lower alkoxy or a heterocyclic group, or a heterocyclic group; R2 is a lower alkyl opti

Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same

A non-polydispersed mixture of conjugates in which each conjugate in the mixture comprises a drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may exhibit higher in vivo activity than a polydispersed mixture of similar conjugates. The mixture may be more effective at surviving an in vitro model of intestinal digestion than polydispersed mixtures of similar conjugates. The mixture may result in less inter-subject variability than polydispersed mixtures of similar conjugates.

Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same

Methods for synthesizing proinsulin polypeptides are described that include contacting a proinsulin polypeptide including an insulin polypeptide coupled to one or more peptides by peptide bond(s) capable of being cleaved to yield the insulin polypeptide with an oligomer under conditions sufficient to couple the oligomer to the insulin polypeptide portion of the proinsulin polypeptide and provide a proinsulin polypeptide-oligomer conjugate, and cleaving the one or more peptides from the proinsulin polypeptide-oligomer conjugate to provide the insulin polypeptide-oligomer conjugate. Methods of synthesizing proinsulin polypeptide-oligomer conjugates are also provided as are proinsulin polypeptide-oligomer conjugates. Methods of synthesizing C-peptide polypeptide-oligomer conjugates and other pro-polypeptide-oligomer conjugates are also provided.